Sponsors ECM2026

At BMS, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We commit to scientific excellence and investment in biopharmaceutical research and development to provide innovative, high-quality medicines that address the unmet medical needs of patients. We apply scientific rigor to produce clinical and economic benefit through medicines that improve patients’ lives. We strive to make information about our commercialized medicines widely and readily available. We actively seek to improve access to care, advocate for policies that promote health equity, and help underserved patients access and afford the medicines they need. We demonstrate ethics, integrity and quality in everything we do for patients, customers and colleagues.

Nordic Bioscience specializes in precision medicine using extracellular matrix Protein Fingerprint biomarkers. All chronic diseases are characterized by an imbalance of the extracellular matrix with elevated levels of either protein formation or degradation. Nordic Biosciences specialized extracellular matrix Protein Fingerprint technology measures the tissue imbalance seen in all chronic diseases.

Nordic Bioscience improve patient care by combining the Protein Fingerprint technology with their expertise in preclinical and clinical research. They assist the improvement of drug development by better selection of patients and reduction of trial length and size.

Nordic Bioscience’s approach is highly scientific, and they are proud to publish their results frequently in leading journals worldwide

FibroFind is a rapidly developing Newcastle-based biomedical sciences company that has a deep understanding of the biology of fibrosis and has employed this knowledge to design bespoke biological assays with human tissues that can determine if a novel drug is able to prevent fibrosis and halt disease. The business focus for FibroFind is their proprietary human fibrosis bioassays that provide a pre-clinical service for pharmaceutical and biotechnology companies developing medicines that target fibrosis. This business model has proved to be highly valued by its growing client base which currently stands at 90 companies based in the USA, Asia and Europe. Despite only beginning trading 3 years ago, FibroFind has already contributed towards new medicines entering into ongoing clinical trials.